DIAPEP-277
drugOn this page
Also known as Diapep277
Summary
Diapep-277 (CHEMBL4297934) is a phase-3 clinical-stage unknown; indicated across 1 condition including type 1 diabetes mellitus.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 1 condition
- Clinical trials: 5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297934 |
| Name | DIAPEP-277 |
| Type | Unknown |
| Max phase | 3 |
Also known as: Diapep-277, Diapep277, DIAPEP277, DIAPEP-277
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| type 1 diabetes mellitus | 3 | MONDO:0005147 | MONDO:0005147 |
Clinical trials
Total trials: 5.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 4 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00615264 | PHASE3 | COMPLETED | Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients |
| NCT00644501 | PHASE3 | COMPLETED | Long-Term Treatment Effect of DiaPep277 in Type 1 Diabetes |
| NCT01103284 | PHASE3 | COMPLETED | Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults |
| NCT01460251 | PHASE3 | TERMINATED | OPen Label Study to Evaluate Long Term Treatment Effect of DiaPep277 |
| NCT00058981 | PHASE2 | TERMINATED | Safety, Tolerability, Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in Latent Autoimmune Diabetes in Adults (LADA) |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: type 1 diabetes mellitus